Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318303 · ClinicalTrials.gov registry record · Phase 2
To Study GSP 301 in Patients With Seasonal Allergic Rhinitis
A Phase 2 study, sponsored by Glenmark Pharmaceuticals Ltd. India.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,111
- Enrollment target
NCT02318303: Completed Phase 2 study, sponsored by Glenmark Pharmaceuticals Ltd. India.
NCT02318303 is a Phase 2 study that has completed, run by Glenmark Pharmaceuticals Ltd. India. The registered enrollment target is 1,111 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (735% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02318303, a Phase 2 study, has completed, sponsored by Glenmark Pharmaceuticals Ltd. India.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,111 participants
- Enrollment target
Study Summary
Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.
Primary Outcome
Subjects were asked to assess rTNSS (reflective Total Nasal Symptom Score), ie, an evaluation of symptom severity over the past 12 hours prior to the recording of the score. The TNSS was defined as the sum of the subject-reported symptom severity scores for the following four nasal symptoms, recorded by each subject in the diary: rhinorrhea, sneezing, nasal congestion, nasal itching. The total rTNSS scores for all four symptoms (i.e, the lowest possible score (0) and the highest possible score
Interventions
- DRUG GSP 301 Placebo NS
- DRUG GSP 301-1 NS (QD)
- DRUG GSP 301-2 NS (BID)
- DRUG Olopatadine HCl-1 NS (QD)
- DRUG Olopatadine HCl-2 NS (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,111 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
What the finished NCT02318303 record still lists
NCT02318303 is an interventional study that assigns participants to a tested intervention. Its 1,111 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (735% higher).
The record links to 0 conditions, and to 5 interventions - of which GSP 301 Placebo NS is the first listed.
NCT02318303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02318303 about?
NCT02318303 is a clinical study titled "To Study GSP 301 in Patients With Seasonal Allergic Rhinitis". Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.
What is the current status of trial NCT02318303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,111 participants. The study started on 2014-12. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02318303?
The interventions under investigation include: GSP 301 Placebo NS (DRUG), GSP 301-1 NS (QD) (DRUG), GSP 301-2 NS (BID) (DRUG), Olopatadine HCl-1 NS (QD) (DRUG), Olopatadine HCl-2 NS (BID) (DRUG).
Who is sponsoring clinical trial NCT02318303?
This trial is sponsored by Glenmark Pharmaceuticals Ltd. India, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02318303's enrollment target sits among peer trials
1,111 21st of 2000 higher than 1,980 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia